KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EBT (2017 - 2026)

Cardlytics filings provide 10 years of EBT readings, the most recent being -$13.8 million for Q1 2026.

  • Quarterly EBT fell 33.73% to -$13.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$104.0 million through Mar 2026, up 40.69% year-over-year, with the annual reading at -$103.5 million for FY2025, 45.33% up from the prior year.
  • EBT hit -$13.8 million in Q1 2026 for Cardlytics, down from -$8.2 million in the prior quarter.
  • Across five years, EBT topped out at $33.0 million in Q1 2022 and bottomed at -$378.3 million in Q4 2022.
  • Average EBT over 5 years is -$53.2 million, with a median of -$15.6 million recorded in 2024.
  • Peak annual rise in EBT hit 232.71% in 2022, while the deepest fall reached 1820.3% in 2022.
  • Cardlytics' EBT stood at -$378.3 million in 2022, then surged by 73.34% to -$100.8 million in 2023, then surged by 84.54% to -$15.6 million in 2024, then soared by 47.08% to -$8.2 million in 2025, then plummeted by 67.25% to -$13.8 million in 2026.
  • Per Business Quant, the three most recent readings for CDLX's EBT are -$13.8 million (Q1 2026), -$8.2 million (Q4 2025), and -$72.7 million (Q3 2025).